Overview of Pharmaco- Economics Methodologies Maher Hassoun, M.S.
|
|
- Abigail Pierce
- 5 years ago
- Views:
Transcription
1 Overview of Pharmaco- Economics Methodologies Maher Hassoun, M.S. Director of Communications, ISPOR Lebanon Chapter (LSPOR) ISPOR Member Country Manager, Mundipharma Lebanon and Jordan
2 Outline Current Challenges Importance and value of Pharmaco Economics Types of Pharmaco Economic Analyses Executive summary and conclusion
3 Background to the Health situation
4 Challenges Payers are increasingly faced with the challenge of maximising health gain with limited health care budgets Payers are now having to make very tough decisions about pharmaceutical spending now and in the future - optimise the use of the healthcare budget Global economic crisis Cost containment/limited health care budgets Ageing population Rising health care expenditure Increasing need for prioritisation 4
5 Health care expenditure as a % of GDP Health care expenditure as a % of GDP has been increasing since 1970, but trends suggest it may now be flattening out OECD Health Data 5
6 Importance of Health Economic Evaluation
7 PE - Introduction Definition: PE is both the science dealing with the value of medicine and the technologies to assess the inherent value of medical interventions. Value is defined as the binary concept involving both the resources committed to a healthcare purpose and the return on that investment or the benefits derived from the commitment of such resources How much will it cost us to do this? How much will we gain if we do this? Without PE we would have no understanding of real costs of diseases. Without such thorough analyses, decision makers will only rely on the cost 7
8 Types of Analyses Cost-of-illness analysis Cost-effectiveness analysis Cost-minimization analysis Cost-benefit analysis Cost-utility analysis 8
9 Types of Analyses Cost-of-illness analysis Cost-effectiveness analysis Cost-minimization analysis Cost-benefit analysis Cost-utility analysis 9
10 Types of Analyses Cost of Illness Cost of Illness analysis (burden of disease analysis) This type of analysis reflects the benefits of an intervention to the society. Furthermore, it identifies and measures the direct and indirect costs of an illness like asthma, CVD, cancer and some other disabling diseases A burden of a disease assesses costs as sum of three components Direct cost o o Medical resources used to treat illness Non medical resources associated with medical service like transportation, lodging for a family, hiring a person to help a family with home care etc Indirect cost: lost productivity due to an illness or disability
11 Types of Analyses- CEA Cost-of-illness analysis Cost-effectiveness analysis Cost-minimization analysis Cost-benefit analysis Cost-utility analysis 11
12 Types of Analyses - CEA Cost Effectiveness analysis (CEA) Cost effectiveness is appropriate when a single dimension of effectiveness characterizes the relevant outcome for all therapies, and competing therapies do not produce an equivalent likelihood of outcomes. This technique is therefore relevant when there is difference in both: The outcome success rate with competing medical interventions The healthcare resources utilized in delivering the treatments
13 Types of Analyses - CEA 13
14 Types of Analyses - CEA Example: Cheapest does not mean necessarily mean best value The price of a course of medicine A is 50 USD and 8 out of 10 patients are treated successfully with this drug, the effectiveness outcome in this example will the rate of successfully treated patients of 8 out of 10 i.e, 80% CE ratio= 50 USD/0.8 = 62.5 USD This may be interpreted as having to spend on average 62.5 USD to treat one patient successfully Medicine B, on the other hand, is sold at 35 USD, but has a success rate of 4 out of 10 patients treated. This implies that the reported effectiveness of drug B is 0.4 (40%), this is translated to a cost per successfully treated patient of: CE ratio= 35 USD/0.4 = 87.5 USD This implies that it will cost on average 87.5 USD to treat a patient successfully Medicine A may have a higher price, but it represents better value in the health delivery system: if only 500 USD is available in our health budget, on average 8 patients can be treated successfully by using medicine A, compared to only 6 if the whole budget had been spent to medicine B
15 How much will it cost us to do this? The example below is based on an actual analysis done in an oncology context. The standard of care was intravenous therapy while the new technology introduced to the market was an oral product. Treatment Standard New technology Drug acquisition cost 3,500 USD 29,000 USD IV administration cost 20,000 USD 0 USD (PO) Hospitalization 1,500 USD 1,000 USD Total treatment cost 25,000 USD 30,000 USD 15
16 How much will it cost us to do this? We would still be making an assumption of equivalent efficacies And even if we added hospitalization to the equation, our decision would still remain consistent. But as you will have realized by now, we are focusing all our efforts on the first economic imperative only: how much will we be paying? That is, we are inherently making an assumption of equivalence as far as benefits are concerned. Perhaps it is time to address the second part of the story Treatment Standard New technology Drug acquisition cost 3,500 USD 29,000 USD IV administration cost 20,000 USD 0 USD (PO) Hospitalization 1,500 USD 1,000 USD 16 Total treatment cost 25,000 USD 30,000 USD
17 And What Are We Getting For That? The benefits associated with these treatment options are indicated as response rates. The following results were reported for the two comparator therapies: Standard Therapy - Response Rate: 17.9% New Technology - Response Rate: 26.6% Treatment Standard New technology Drug acquisition cost 3,500 USD 29,000 USD IV administration cost 20,000 USD 0 USD (PO) Hospitalization 1,500 USD 1,000 USD Total treatment cost 25,000 USD 30,000 USD 17
18 And The Value? The value will be indicated as the ratio of benefits to costs. We can calculate: The average cost effectiveness ratio (ACER), a parameter representing the inherent value of a single intervention in isolation For this example, the ACER associated with standard therapy is: - Cost Per Responder - Standard Therapy: R25,000/17.9% = R139,665 While the ACER for the oral therapy can be described as: R30,000/26.6% = R112,782 Treatment Standard New technology Drug acquisition cost 3,500 USD 29,000 USD IV administration cost 20,000 USD 0 USD (PO) Hospitalization 1,500 USD 1,000 USD 18 Total treatment cost 25,000 USD 30,000 USD
19 Types of Analyses Cost-of-illness analysis Cost-effectiveness analysis Cost-minimization analysis Cost-benefit analysis Cost-utility analysis 20
20 Types of Analyses - CMA Cost Minimization analysis (CMA) This analytical technique is applied in situations where outcomes associated with two (or more) alternatives are equivalent and the objective is thus to compare the total resource costs that are associated with different treatments
21 Types of Analyses - CMA Cheaper does not necessarily mean best value 22
22 Types of Analyses Cost-of-illness analysis Cost-effectiveness analysis Cost-minimization analysis Cost-benefit analysis Cost-utility analysis 23
23 Types of Analyses - CBA 24
24 Types of Analyses - CBA 25
25 Types of Analyses Cost-of-illness analysis Cost-effectiveness analysis Cost-minimization analysis Cost-benefit analysis Cost-utility analysis 26
26 Types of Analyses - CUA CUA is the only method available for measuring multiple outcomes into single parameter
27 Types of Analyses - CUA How a QALY is calculated? Patient x has a serious, life-threatening condition. - If he continues receiving standard treatment he will live for 1 year and his quality of life will be If he receives the new drug he will live for 1 year 3 months (1.25 years), with a quality of life of 0.6. The new treatment is compared with standard care in terms of the QALYs gained: Standard treatment: 1 (year's extra life) x 0.4 = 0.4 QALY New treatment: 1.25 (1 year, 3 months extra life) x 0.6 = 0.75 QALY Therefore, the new treatment leads to 0.35 additional QALYs (that is: QALY = 0.35 QALYs). The cost of the new drug is assumed to be $10,000, standard treatment costs $3000. The difference in treatment costs ($7000) is divided by the QALYs gained (0.35) to calculate the cost per QALY. So the new treatment would cost $20,000 per QALY. 28 -QALY = Utility x # years in health state -One year at full health QALY = 1.0 -Death QALY = 0.0
28 Executive Summary Decision Making Criteria Have Changed From Price alone Towards Cost Effectiveness and Added Value 33
29 Executive Summary Conclusions Health Economics is about the right allocation of healthcare expenditure to ensure optimal medical conditions for patients as much as possible 34
30 35
Introduction of Health Economics
Introduction of Health Economics Prof. Jie Chen Health Technology Assessment & Research Center Fu Dan University 4 th March, 2004 Outline Why economics for healthcare services? Some basic economic concepts
More informationAN OVERVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH
Int. J. LifeSc. Bt & Pharm. Res. 2012 Harika Javangula, 2012 Review Article ISSN XXXX-XXXX www.ijlbpr.com Vol.1, Issue. 1, January 2012 2012 IJLBPR. All Rights Reserved AN OVERVIEW OF PHARMACOECONOMICS
More informationWhat can Health Economics do for you?
Incorporating Health Economics into Grant Proposals Health Economics Short Course For more information and course dates, please visit our website: http://go.unimelb.edu.au/i8ba Or email us: health-economics@unimelb.edu.au
More informationASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning S P ECONOMIC EVALUATION IN HEALTH CARE
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning ECONOMIC EVALUATION IN HEALTH CARE Outline of the Session 1. What is Economic Evaluation? 2. Why do Economic
More informationIntroduction to Pharmacoeconomics. Almut G. Winterstein, Ph.D.
Introduction to Pharmacoeconomics Almut G. Winterstein, Ph.D. Why do we need Health Economics? Suppose you are comparing two drugs or services where one is more expensive than the other. In choosing the
More informationASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning S P ECONOMIC EVALUATION IN HEALTH CARE
ASAP Regional Training on Epidemiological and Economic Tools for HIV/AIDS Strategic Planning ECONOMIC EVALUATION IN HEALTH CARE Outline of the Session 1. What is Economic Evaluation? 2. Why do Economic
More informationEconomic Evaluations in Health An introduction for clinicians, researchers, and policy makers
Economic Evaluations in Health An introduction for clinicians, researchers, and policy makers Philip Leonard, PhD, MSSU and UNB Economics May 16, 2016 Saint John Regional Hospital, NB Economics in health
More informationEconomic Evaluation: Making the case for diabetes selfmanagement
Economic Evaluation: Making the case for diabetes selfmanagement education NACDD Webinar Series Session 2: Applying Economic Evaluation October 4, 2012 Carsten Baumann, MA DSME Webinar Series Blueprint
More informationEfficiency: Concepts and Methods. Hui Ru Chang Department of Medical Affairs, Mackay Memorial Hospital May 25, 2010
Efficiency: Concepts and Methods Hui Ru Chang Department of Medical Affairs, Mackay Memorial Hospital May 25, 2010 1 Contents 2 What is Efficiency? Methods of Assessing Efficiency Cost Effectiveness Analysis
More informationStep by step guide to economic evaluation in cancer trials
What is CREST? The Centre for Health Economics Research and Evaluation (CHERE) at UTS has been contracted by Cancer Australia to establish a dedicated Cancer Research Economics Support Team (CREST) to
More informationEconomic Evaluation of Health Care
Economic Evaluation of Health Care (Evaluasi Ekonomi untuk Pelayanan Kesehatan) Getting the best value for health spending Prof. dr. Bhisma Murti, MPH, MSC, PhD Institute of Health Economic and Policy
More informationHEALTHCARE: INTRODUCTION MAIN ISSUES IDENTIFIED BY THE COMMITTEE:
HEALTHCARE: The Future of Health in Estonia Multi-Sector Collaboration to Ensure Proper Business Climate, Healthy Workforce, and Attractiveness for Current & Future Investment INTRODUCTION The Estonian
More informationPOLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS. (project)
POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS Ewa Orlewska 1, Piotr Mierzejewski 1,2 (project) 1 Department of Experimental and Clinical Pharmacology, Medical University of Warsaw Head
More informationMarket Access Strategy and Planning: Succeeding in the Age of Value-based Reimbursement
Market Access Strategy and Planning: Succeeding in the Age of -based Reimbursement Presented by: Michael J. Lacey, Senior Director, Strategic Consulting (Life Sciences) Date: March 01, 2017 Truven Health
More informationThe Use of Pharmacoeconomic Principles in Local Drug Policy Decisions in Poland
The Use of Pharmacoeconomic Principles in Local Drug Policy Decisions in Poland Prof. Karina Jahnz-Różyk Dr Joanna Lis ISPOR 16th Annual European Congress Dublin Ireland Pharmacoeconomics is formally stated
More informationFiscal Implications of Chronic Diseases. Peter S. Heller SAIS, Johns Hopkins University November 23, 2009
Fiscal Implications of Chronic Diseases Peter S. Heller SAIS, Johns Hopkins University November 23, 2009 Defining Chronic Diseases of Concern Cancers Diabetes Cardiovascular diseases Mental Dementia (Alzheimers
More informationPrecision Medicine. A Health Economic perspective
Precision Medicine. A Health Economic perspective Lieven Annemans Ghent University Lieven.annemans@ugent.be April 2018 1 Exponential technology exponential cost? http://medicalfuturist.com 2 Total public
More informationECONOMIC VALUE OF VACCINES
ECONOMIC VALUE OF VACCINES ISPOR Forum of the Economic Value Assessment of Vaccines Designed to Prevent Infectious Disease Task Force Monday, May 23, 2016 Outline for the Forum Task Force Leadership Group
More informationValue Assessment Frameworks: How Can They Meet The Challenge?
Page 1 of 5 Value Assessment Frameworks: How Can They Meet The Challenge? Robert Dubois, Kimberly Westrich, et al. March 2, 2017 Rising health care costs and pharmaceutical prices in particular are among
More informationHTA and Submissions. Ferg Mills, Angela Rocchi April 5, Agenda
HTA and Submissions Ferg Mills, Angela Rocchi April 5, 2017 Agenda The Decision Problem Role of HTA bodies in Canada CADTH, pcodr and INESSS Overview of the elements of the HTA submission Clinical package
More informationPrescription Medicines: Costs in Context. Updated August 2016
Prescription Medicines: Costs in Context Updated August 2016 Medicines are Transforming the Treatment OF DEVASTATING DISEASES HEPATITIS C The leading cause of liver transplants and the reason liver cancer
More informationChanges in the regulatory environment: The EU economic assessment study
Changes in the regulatory environment: The EU economic assessment study Dr Peter Varnai Technopolis Group 8 February 2018 Introduction Present the independent study of the economic impact of the Paediatric
More informationICER Value Assessment Framework: 1.0 to 2.0
ICER Value Assessment Framework: 1.0 to 2.0 Outline Background on ICER Version 1.0 development Conceptual basis for ICER value assessment framework Domains of value Long-term perspective (value for money)
More informationNATIONAL POLICY IN HEALTH FINANCING
NATIONAL POLICY IN HEALTH FINANCING 5 th Congress Indonesia Health Economics Association ( InaHea) Jakarta, 31 st Oct 2018 PRESENTATION OUTLINE Introduction Overview of Indonesia s Health Financing Evaluation
More informationValue Based Contracting
Value Based Contracting CONCEPTS FOR THE MEDICAL PRACTICE dhgllp.com/healthcare 225 Peachtree Street NE, Suite 600 Atlanta, GA 30303 Bill Hannah PRINCIPAL Bill.Hannah@dhgllp.com 404.575.8921 Doral Davis-Jacobsen
More informationDo Novel Value Measures Have a Place in European HTA?: A U.S. Health Economist Perspective
Do Novel Value Measures Have a Place in European HTA?: A U.S. Health Economist Perspective ISPOR-EU panel presentation, Monday Nov 12, 2018, 3.45-4.45pm [Breakout Session #2 (IP6)] November 12, 2018 Barcelona
More informationRecommendations of the Panel on Cost- Effectiveness in Health and Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationReimbursement of Oncology Drugs in Saudi Arabia
Reimbursement of Oncology Drugs in Saudi Arabia Abdulaziz Al-Saggabi, B.Sc., M.Sc., Pharm.D. Director, Drug Policy & Economics Center Ministry of National Guard Health Affairs Chairman, ISPOR Arabic Network
More informationQualità della Vita Legata allo Stato di Salute in Farmacoeconomia
Qualità della Vita Legata allo Stato di Salute in Farmacoeconomia Luciana Scalone, PharmD, DSc Centro di Farmacoeconomia Università degli Studi di Milano Problem Needs are unlimited resources are limited
More informationThis report summarizes the major arguments put forward by Richard Lane & Kara Hanson, Faculty of Public Health, London School of Hygiene and Tropical
This report summarizes the major arguments put forward by Richard Lane & Kara Hanson, Faculty of Public Health, London School of Hygiene and Tropical Medicine. In this podcast produced by the Lancet, they
More informationEconomic evaluations are defined as the comparative analysis of alternative
Nyman Economic Evaluations in Healthcare: Overview, Policy, and Uses John A. Nyman, PhD Overview: The Basics Economic evaluations are defined as the comparative analysis of alternative courses of action
More informationHealth and well-being in times. WHO Regional Director for Europe
Health and well-being in times of austerity Zsuzsanna Jakab Zsuzsanna Jakab WHO Regional Director for Europe Why Health 2020? Financial and economic crisis is threatening the gains made across Europe in
More informationLuciana Scalone. Centro di Farmacoeconomia Università degli Studi di Milano. Problem
Qualità della Vita Legata allo Stato di Salute in Farmacoeconomia Luciana Scalone Centro di Farmacoeconomia Università degli Studi di Milano Problem Needs are unlimited resources are limited Resources
More informationCriteria and Guidelines for the Analysis of Long-Term Impacts on Healthcare Costs and Public Health California Health Benefits Review Program
Criteria and Guidelines for the Analysis of Long-Term Impacts on Healthcare Costs and Public Health California Health Benefits Review Program The California Health Benefits Review Program (CHBRP) must
More informationPIP DATA FOR MARKET ACCESS
PIP DATA FOR MARKET ACCESS By Mark Nuijten, PhD, MD, MBA Maart 13, 2012 London, UK GENERAL TRENDS IN HEALTH CARE SYSTEMS IN EUROPE Health Care Systems Budget Constraints Inceasing demand for health care
More informationA decision-analytic approach for supporting healthcare resource allocation
A decision-analytic approach for supporting healthcare resource allocation, Yrjänä Hynninen, and Ahti Salo Aalto University School of Business, Department of Information and Service Economy Aalti University
More informationEvaluating the Value of New Drugs and Devices
Evaluating the Value of New Drugs and Devices Copyright ICER 2015 The ICER Value Framework The problems the value framework was intended to address Poor reliability and consistency of value determinations
More informationCost-Effectiveness Analysis: The Bare Essentials
Cost-Effectiveness Analysis: The Bare Essentials Michael K. Gould, MD, MS Director for Health Services Research and Implementation Science Department of Research and Evaluation Kaiser Permanente Southern
More informationLA COPERTURA DEI SERVIZI SANITARI NEI PAESI OCSE. Annalisa Belloni
LA COPERTURA DEI SERVIZI SANITARI NEI PAESI OCSE Annalisa Belloni Agenda Com è organizzata la copertura sanitaria? Come misurarla? Quali cambiamenti e quale impatto? Il ruolo dell HTA Three Dimensions
More informationEvaluating the value of new drugs
Evaluating the value of new drugs The ICER value framework The framework includes Content A list of elements to consider Measurement options Methods to measure or judge each element Assessment process
More informationBalancing the Goals of Health Care Provision
Balancing the Goals of Health Care Provision Martin Feldstein 1 I am delighted to see so many of you here at this lunch. When I first started working on the economics of health care more than 40 years
More informationMethodology to assess the cost impact of PMB benefit definitions
Methodology to assess the cost impact of PMB benefit definitions Version 1.0.0 07 March 2012 Contents 1 Background... 1 2 Aim... 1 3 Objectives... 1 4 Methods... 2 5 Variables for data collection, data
More informationThe ICER Value Framework: The Importance of Empirical Estimates of Opportunity Costs
The ICER Value Framework: The Importance of Empirical Estimates of Opportunity Costs Steven D. Pearson, MD, MSc The ICER Value Framework Takes a population level perspective as opposed to trying to serve
More informationMedical Research: What s it worth? Estimating the economic benefits from medical research in the UK
Medical Research: What s it worth? Estimating the economic benefits from medical research in the UK Briefing November 2008 Summary This briefing describes the outcomes of a one-year study into the economic
More informationThe Value of Expanded Pharmacy Services in Canada Recommendations for Optimized Practice
The Value of Expanded Pharmacy Services in Canada Recommendations for Optimized Practice Louis Thériault Vice-President, Industry Strategy and Public Policy The Conference Board of Canada April 25, 2017
More informationInsights into pharmacy benefit management, drug trend and the future
Insights into pharmacy benefit management, drug trend and the future 1 Where does your health care dollar go? 2 Pharmacy share of total health spend 25% 21% 20% 19% 15% 10% 10% 5% 0% Retail Drugs as a
More informationPRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES
PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES We at Sanofi work passionately, every day, to understand and solve health care needs of people across the world. We are dedicated to therapeutic
More informationLARC: Return on Investment Virtual Learning Session. August 2, :00-4:00p ET For Audio: , ext #
LARC: Return on Investment Virtual Learning Session August 2, 2016 2:00-4:00p ET For Audio: 866-740-1260, ext. 5273187# Agenda 2:00 Welcome and Introductions 2:10 Basics of Economic Analysis and Return
More informationValuing Medical Innovation Perspectives matter. Lara Verdian 10 September 2015
Valuing Medical Innovation Perspectives matter Lara Verdian 10 September 2015 1965 1967 1969 1971 1973 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013
More information250 Dundas Street West, Suite 500 Toronto ON, M5T 2Z5 (Contact)
Feedback submitted to the Patented Medicines Pricing Review Board from the Multiple Sclerosis Society of Canada related to Excessive Drug Pricing in Canada Deadline: Monday, October 24, 2016 Submitted
More informationWelcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications
AMCP Partnership Forum Designing Benefits and Payment Models for Innovative High Investment Medications Welcome Bri Palowitch, PharmD, BCGP Manager, Pharmacy Affairs Academy of Managed Care Pharmacy Disclaimer
More informationOverview of Reimbursement Strategies for Novel Medical Technologies
Overview of Reimbursement Strategies for Novel Medical Technologies Nov 9, 2016 Goals and Objectives Develop understanding of U.S. medical technology reimbursement landscape and provide information about
More informationHealth Savings Accounts: An Employer Overview
Health Savings Accounts: An Employer Overview Since salary alone is often not enough to attract and retain valued employees, what can your business do to enhance its employee benefits package? Table of
More informationDecision Rules. Kevin Frick, PhD. Johns Hopkins University
Decision Rules Kevin Frick, PhD Johns Hopkins University Decision Rules for Cost-Benefit Analysis Section A Variations on Decision Rules Covered in this session Non-budget constrained CBA Budget constrained
More informationValue-Based Pricing Working Party #1: Briefing for DH presentation
Value-Based Pricing Working Party #1: Briefing for DH presentation This document provides background material for the DH presentation to the first Working Party on the implementation of value assessment
More informationMedicare Prescription Drug, Improvement and Modernization Act
International Journal of Health Research and Innovation, vol. 1, no. 2, 2013, 13-18 ISSN: 2051-5057 (print version), 2051-5065 (online) Scienpress Ltd, 2013 Medicare Prescription Drug, Improvement and
More informationDemonstrating Value of Medicines Through Health Economic and Outcomes Evidence
Demonstrating Value of Medicines Through Health Economic and Outcomes Evidence Eleni Samaras Allen, PharmD March 22, 2016 Kissimmee, FL Disclaimer The views and opinions expressed in the following PowerPoint
More informationFinancing the future HSC achieving sustainability?
Financing the future HSC achieving sustainability? Julie Thompson Senior Director of Finance, DoH NI Owen Harkin - Vice Chair of HFMA and Director of Finance, NHSCT The Story so Far DHSSPS Policy & Strategy
More informationAn Insight on Health Care Expenditure
An Insight on Health Care Expenditure Vishakha Khanolkar MBA Student The University of Findlay Simeen A. Khan MBA Student The University of Findlay Maria Gamba Associate Professor of Business The University
More informationMemberChoice FORMULARY MANAGEMENT MEDICATION THERAPY MANAGEMENT (MTM) SPECIALTY DRUG MANAGEMENT. Specialty Drug Management
MemberChoice FORMULARY MANAGEMENT MEDICATION THERAPY MANAGEMENT (MTM) SPECIALTY DRUG MANAGEMENT SPECIALTY DRUG MANAGEMENT 1 1% Prescriptions Written in 2012 99% 25% Prescription Drug Spending in 2012 75%
More informationThe Institute for Clinical and Economic Review s Use of FDA Approval Volume to Calculate Budget Impact Thresholds: A Scenario Analysis
The Institute for Clinical and Economic Review s Use of FDA Approval Volume to Calculate Budget Impact Thresholds: A Scenario Analysis 7.24.18 Avalere Health T 202.207.1300 avalere.com An Inovalon Company
More informationHSPM 818: Economic Evaluation and Policy Analysis of Health Services. Fall Semester 2011, Week 1: Introduction Assistant Professor Brian Chen
HSPM 818: Economic Evaluation and Policy Analysis of Health Services Fall Semester 2011, Week 1: Introduction Assistant Professor Brian Chen Introductions Course description Course objective Assignments
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: United Kingdom Year of Disclosure: 2017
More informationHealthcare Financial Management, M.S.
Healthcare Financial Management, M.S. 1 Healthcare Financial Management, M.S. FOX SCHOOL OF BUSINESS AND MANAGEMENT (http://www.fox.temple.edu) About the Program This program is not accepting applications
More informationCo-payments, Choices and Coverage: Meeting the Challenge of Health Financing for Consumers
Co-payments, Choices and Coverage: Meeting the Challenge of Health Financing for Consumers Dr Sharon Willcox, Health Policy Solutions Catholic Health Australia National Conference 27 August 2013 OUTLINE
More informationModelling and Health Economics
EACS HIV Summer School 2018 Modelling and Health Economics Valentina Cambiano UCL Institute of Global Health 1 st September 2018 Conflict of Interests No conflict of interests to declare. 2 Outline What
More informationRISK SHARING AGREEMENTS: COUNTRY EXPERIENCES, CHALLENGES, AND LESSONS LEARNED
THIRD PLENARY: Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned Jöerg Mahlich, PhD Janssen Pharmaceutical Neuss, Germany RISK SHARING AGREEMENTS: COUNTRY EXPERIENCES, CHALLENGES,
More informationOptional Group Critical Illness. Financial support at a critical time
Optional Group Critical Illness Financial support at a critical time Medical advances have greatly increased the ability of Canadians to survive a critical illness. However, few of us are prepared for
More informationNOVEL APROACHES TO VALUE: BEYOND COST EFFECTIVENESS. Novel Approaches to Value Assessment, Beyond Cost- Effectiveness Framework
Novel Approaches to Value Assessment, Beyond Cost- Effectiveness Framework Charles Phelps, PhD University of Rochester Rochester, NY, USA NOVEL APROACHES TO VALUE: BEYOND COST EFFECTIVENESS Charles E.
More informationMulti-stakeholder participations in priority setting processes:
International Health Policy Program -Thailand International Health Policy Health Program Policy -Thailand Program -Thailand Multi-stakeholder participations in priority setting processes: Health Financing
More informationCo-financing mechanisms Budget cap Pay back Risk-sharing instruments Reimbursement tax
LINKING TODAY S DECISIONS WITH TOMORROW S POSSIBILITIES: HTA: LINKING TODAY S DECISIONS WITH TOMORROW S POSSIBILITIES: A PERSPECTIVE FROM POLAND, HUNGARY, GREECE AND SERBIA A PERSPECTIVE FROM POLAND Speakers:
More informationPredictive Analytics in the People s Republic of China
Predictive Analytics in the People s Republic of China Rong Yi, PhD Senior Consultant Rong.Yi@milliman.com Tel: 781.213.6200 4 th National Predictive Modeling Summit Arlington, VA September 15-16, 2010
More informationA New Ownership Society in Health Care
A New Ownership Society in Health Care Consumer-Driven Healthcare Summit September 26, 2007 James C. Robinson Editor-in-Chief, Health Affairs OVERVIEW The old ownership society: consumerism Towards a new
More informationCompensation and Reimbursement
492 Pharmacy Management: Compensation and Reimbursement Positions Compensation and Reimbursement Revenue Cycle Compliance and Management (1710) To encourage pharmacists to serve as leaders in the development
More informationLawyer Chief Expert at the Ministry of Health
by Jakub Adamski Vienna, 30/09/2011 Lawyer Chief Expert at the Ministry of Health participation in European Commission and Council working groups member of the EUCERD coordination of works of the Rare
More informationTHE FUTURE OF ROCKEFELLER INSIGHTS. David K. Song, M.D., Ph.D., CFA Senior Portfolio Manager and Managing Director
ROCKEFELLER INSIGHTS THE FUTURE OF H E A LT H C A R E David K. Song, M.D., Ph.D., CFA Senior Portfolio Manager and Managing Director Rolando Morillo Equity Analyst and Vice President R O C K C O.C O M
More informationAffordable Access to Medications Brief to the Department of Health Fair Drug Prices Consultation Submitted August 13, 2011
Affordable Access to Medications Brief to the Department of Health Fair Drug Prices Consultation Submitted August 13, 2011 Executive Summary and Recommendations The MS Society of Canada, Atlantic Division
More informationIMS Brogan Private Drug Plan Drug Cost Forecast Commissioned by Rx&D Canada s Research-Based Pharmaceutical Companies
IMS Brogan Private Drug Plan Drug Cost Forecast 2013-2017 Commissioned by Rx&D Canada s Research-Based Pharmaceutical Companies Overview 1. Who are Rx&D and IMS Brogan? 2. Environment 3. Background 4.
More informationModerator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
More informationNagement. Revenue Scotland. Risk Management Framework. Revised [ ]February Table of Contents Nagement... 0
Nagement Revenue Scotland Risk Management Framework Revised [ ]February 2016 Table of Contents Nagement... 0 1. Introduction... 2 1.2 Overview of risk management... 2 2. Policy Statement... 3 3. Risk Management
More informationCost-effectiveness analysis: Balancing value with affordability?
AMCP Webinar Cost-effectiveness analysis: Balancing value with affordability? Michael Drummond, Dan Danielson and Steven D. Pearson MODERATOR: Michael Drummond, PhD University of York UK 1 Cost-Effectiveness
More informationCigna Administrative Policy
Cigna Administrative Policy Subject Clinical Trials Table of Contents Administrative Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/15/2014 Administrative
More informationHealth System and Policies of China
of China Yang Cao, PhD Associate Professor China Pharmaceutical University Nanjing, China Transformation of Healthcare Delivery in China Medical insurance 1 The timeline of the medical and health system
More informationACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS. Supporting employees and building sustainable drug plans...together
ACTIVELY MANAGED DRUG SOLUTIONS SPECIALTY DRUGS Supporting employees and building sustainable drug plans...together Not available in the province of Quebec INTRODUCING THE SPECIALTY DRUG PROGRAM If you
More informationMACRAnomics. Patient-Level Economics and Strategic Implications for Providers. Presented to: NW Ohio HFMA October 20, 2016
MACRAnomics Patient-Level Economics and Strategic Implications for Providers Presented to: NW Ohio HFMA October 20, 2016 Property of HealthScape Advisors Strictly Confidential 2 MACRAnomics: Objectives
More informationWorkers Compensation Basics
Workers Compensation Basics What is work comp and what does it cover? Workers compensation coverage is an employee benefit that is mandated by law, which differs by each state, and covers employees for
More informationWhere does the typical health insurance dollar go?
Where does the typical health insurance dollar go? 87 13 Inpatient Services = 20 Outpatient Services = 15 Hospital Costs = 35 Based on a PricewaterhouseCoopers analysis. Factors Fueling Rising Healthcare
More informationDeveloping and implementing protective measures for ELF EMF. - a public health economics perspective
Developing and implementing protective measures for ELF EMF - a public health economics perspective Dan Chisholm, PhD 1 Objectives 1. Rationale for an economic perspective (WHY?) Use / distribution of
More informationThe JAMS COI Management Guidance on Eligibility Criteria for Clinical Practice Guideline Formulation March, 2017
The JAMS COI Management Guidance on Eligibility Criteria for Clinical Practice Guideline Formulation March, 07 Table of Contents. Background. Those subject to COI management. Disclosure items and self-disclosure
More informationPhRMA Perspective: Government Policies to Support Innovative Contracting Approaches
PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches CBI s PAP 2017 Michelle Drozd, Deputy Vice President Policy & Research Department October 12, 2016 Agenda Recent trends
More informationGlobal Plan to End TB THE EXECUTIVE SUMMARY. a partnership hosted by United Nations at
Global Plan to End TB THE SHIFTPARADIGM 2016-2020 EXECUTIVE SUMMARY a partnership hosted by United Nations at The UN Sustainable Development Goals (Global Goals) and the End TB Strategy aim to end tuberculosis
More informationWhite Paper: Formulary Development at Express Scripts
White Paper: Formulary Development at Express Scripts Express Scripts works with health-benefit plan sponsors and individual members of health plans to provide affordable access to clinically sound, high-quality
More informationChallenges of implementation. a regulatory perspective
Challenges of implementation of ICH Q 9 a regulatory perspective Jacques Morénas Deputy Director Inspectorate and Companies Department The French Health Products Safety Agency (AFSSAPS) telephone : 33
More informationWhat are the projections for the future elderly in Europe? What policies may be needed?
What are the projections for the future elderly in Europe? What policies may be needed? Vincenzo Atella, Federico Belotti, Joanna Kopinska, Alessandro Palma, Andrea Piano Mortari April 5 th, 2018 Outline
More informationINFORMATION ABOUT MEDICARE A GUIDE FOR PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS
INFORMATION ABOUT MEDICARE A GUIDE FOR PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS HOW TO CHOOSE A MEDICARE PLAN If you are living with relapsing multiple sclerosis (RMS), you have a lot to think about. One
More informationCritical Illness Insurance from Bankers Life
Critical Illness Insurance from Bankers Life Underwritten by Bankers Life and Casualty Company 18726C Critical Illness Insurance Solicitation. THESE POLICIES PROVIDE LIMITED BENEFITS. Risk of critical
More information2. Risk exists, government intervention is required, regulation is best alternative
Introduction & Background Response to the Health Canada Consultation Document This response to the consultation document has been prepared by Neil Palmer, Founder and Principal Consultant of PDCI Market
More informationMyth: This is going to cost a fortune. How will we pay for it?
Myths About SB 810 & Responses I. AFFORDABILITY Myth: This is going to cost a fortune. How will we pay for it? Response: The current health care finance system wastes nearly 50% of each health care dollar
More informationPresented by: Steven Flores. Prepared for: The Predictive Modeling Summit
Presented by: Steven Flores Prepared for: The Predictive Modeling Summit November 13, 2014 Disease Management Introduction A multidisciplinary, systematic approach to health care delivery that: Includes
More informationGuidelines for the Budget Impact Analysis of Health Technologies in Ireland
Guidelines for the Budget Impact Analysis of Health Technologies in Ireland 2014 1 About the Health Information and Quality Authority The (HIQA) is the independent Authority established to drive continuous
More information